



(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/381 (2006.01)
C07D 495/04 (2006.01) A61P 35/00 (2006.01)
C07D 519/00 (2006.01) A61P 37/00 (2006.01)
A61K 31/4985 (2006.01)

(21) International Application Number:

PCT/US2012/063198

(22) International Filing Date:

2 November 2012 (02.11.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/555,395 3 November 2011 (03.11.2011) US

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 DNA Way,
South San Francisco, California 94080 (US).

(72) Inventors: **CRAWFORD, James John**; c/o Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080
(US). **YOUNG, Wendy B.**; c/o Genentech, Inc., 1 DNA
Way, South San Francisco, California 94080 (US).

(74) Agents: **ANDRUS, Alex** et al.; Genentech, Inc., 1 DNA
Way, MS 49, South San Francisco, California 94080 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY



(I)

(57) Abstract: Alkylated piperazine compounds of
Formula I are provided, including stereoisomers, tau-
tomers, and pharmaceutically acceptable salts thereof,
useful for inhibiting Btk kinase, and for treating im-
mune disorders such as inflammation mediated by Btk
kinase. Methods of using compounds of Formula I for
in vitro, *in situ*, and *in vivo* diagnosis, and treatment of
such disorders in mammalian cells, or associated
pathological conditions, are disclosed.